A new era in chronic spontaneous urticaria: FDA approval of the oral BTK inhibitor remibrutinib. [PDF]
Jan M +5 more
europepmc +1 more source
Cryptococcal Infection in a Patient With Chronic Lymphocytic Leukaemia Receiving Acalabrutinib, a Bruton's Tyrosine Kinase Inhibitor: A Case Report. [PDF]
Al-Shaker AN +3 more
europepmc +1 more source
BTK blocks the inhibitory effects of MDM2 on p53 activity
Miran Rada +7 more
openalex +2 more sources
Altered PTPN13-β-catenin interaction by pathogenic mutations and involvement of this axis in B-cell receptor signalling. [PDF]
Cabrera-Riofrío DA +7 more
europepmc +1 more source
Ibrutinib: The BTK Inhibitor Used for Hematologic Maligancies.
Monika Jain +3 more
openalex +1 more source
PLCG2 across human disease: genetic variants, signaling mechanisms, and clinical implications. [PDF]
Jiang P +8 more
europepmc +1 more source
Preliminary Safety and Efficacy of Emavusertib (CA-4948) in Combination with Ibrutinib in Relapsed/Refractory Primary Central Nervous System Lymphoma Patients with Prior Exposure to BTK Inhibitor [PDF]
Grzegorz S. Nowakowski +15 more
openalex +1 more source

